Imatinib Teva Uk

Imatinib, the active ingredient in Imatinib Teva Uk, is a tyrosine kinase inhibitor presented as a strength/form for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.\n\nGNH India supplies Imatinib Teva Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib acts on BCR‑ABL driven malignancies and related tyrosine‑kinase pathways.\n\nChronic Myeloid Leukemia: reduces leukemic cell proliferation and improves long‑term survival.\nGastrointestinal Stromal Tumor: blocks tumor growth and delays disease progression.\nPhiladelphia chromosome‑positive Acute Lymphoblastic Leukemia: induces remission by targeting the BCR‑ABL fusion protein.

Imatinib may cause a range of adverse reactions, from mild to severe.\n\nCommon Side Effects:\n- Nausea and vomiting\n- Peripheral edema\n- Muscle cramps or pain\n- Fatigue or weakness\n- Diarrhea\n- Skin rash or itching\n\nSerious or Rare Side Effects:\n- Neutropenia or severe leukopenia\n- Thrombocytopenia\n- Hepatotoxicity with elevated liver enzymes\n- Cardiac failure or reduced left‑ventricular function\n- Severe skin reactions such as Stevens‑Johnson syndrome\n- Pulmonary hypertension or interstitial lung disease

Before initiating therapy, clinicians should assess baseline health status and monitor patients regularly.\n\nMonitor blood counts: perform complete blood count at baseline and periodically.\nAssess liver function: check hepatic enzymes before treatment and during therapy.\nEvaluate cardiac function: perform ECG or echocardiogram in patients with cardiac risk factors.\nAvoid in patients with known hypersensitivity to imatinib or its excipients.\nUse caution in renal impairment: adjust monitoring frequency as needed.\nStore at below 25°C: keep in the original packaging, protect from moisture and light.

Imatinib can interact with several medicines that affect its metabolism or increase toxicity.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may raise imatinib levels.\n- Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) – may reduce efficacy.\n- Concomitant use with QT‑prolonging agents – risk of cardiac arrhythmia.\n\nModerate Interactions (Monitor Closely):\n- CYP3A4 substrates (e.g., midazolam, cyclosporine) – may require dose adjustment.\n- Drugs that alter gastric pH (e.g., omeprazole) – may affect absorption.\n- Live vaccines – potential for reduced immune response.